CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Update

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) was the target of a large increase in short interest in October. As of October 15th, there was short interest totalling 1,110,000 shares, an increase of 63.5% from the September 30th total of 679,000 shares. Based on an average daily volume of 13,620,000 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in CNS Pharmaceuticals stock. Virtu Financial LLC increased its position in shares of CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) by 616.6% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 94,246 shares of the company’s stock after purchasing an additional 81,094 shares during the quarter. Virtu Financial LLC owned approximately 0.80% of CNS Pharmaceuticals worth $34,000 at the end of the most recent quarter. 14.02% of the stock is owned by institutional investors.

CNS Pharmaceuticals Stock Performance

Shares of NASDAQ:CNSP opened at $0.13 on Friday. The company has a market cap of $190,764.60, a PE ratio of 0.00 and a beta of 2.57. CNS Pharmaceuticals has a 52 week low of $0.10 and a 52 week high of $137.50. The firm has a 50 day simple moving average of $0.14 and a 200 day simple moving average of $3.62.

CNS Pharmaceuticals (NASDAQ:CNSP) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($6.72) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Separately, Maxim Group raised shares of CNS Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price objective for the company in a research report on Tuesday, September 10th.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.